Neuphoria Therapeutics Inc. Contingent Consideration Classified as Equity, Fair Value Disclosure
Neuphoria Therapeutics Inc. (NEUP) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $587.76 thousand as of 2024-06-30, per its 10-K filed 2024-09-30.
Financial Statements › Notes
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2024-09-30
- 2024-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $587.76K.
- 2023-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $2.46M.
- 2022-06-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $1.86M.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2024-06-30 | $587.76K 10-K · filed 2024-09-30 |
| 2023-06-30 | $2.46M 10-K · filed 2024-09-30 |
| 2022-06-30 | $1.86M 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |